Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Maughan, Benjamin Louis
Suzman, Daniel L.
Nadal, Rosa
Bassi, Sunakshi
Schweizer, Michael Thomas
Antonarakis, Emmanuel S.
机构：
[1] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.252
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
252
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Optimal Sequencing of Docetaxel and Abiraterone in Men With Metastatic Castration-Resistant Prostate Cancer
    Maughan, Benjamin L.
    Xhou, Xian C.
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael T.
    Antonarakis, Emmanuel S.
    [J]. PROSTATE, 2015, 75 (15): : 1814 - 1820
  • [2] Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa Maria
    Bassi, Sunakshi
    Antonarakis, Emmanuel S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [3] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC): Effect of early docetaxel on outcomes.
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [5] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study
    Maughan, Benjamin L.
    Luber, Brandon
    Nadal, Rosa
    Antonarakis, Emmanuel S.
    [J]. PROSTATE, 2017, 77 (01): : 33 - 40
  • [7] Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study
    Azuma, Takeshi
    [J]. PROSTATE, 2018, 78 (04): : 278 - 278
  • [8] INTERMITTENT (RECHALLENGE) CHEMOTHERAPY WITH DOCETAXEL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Bracarda, Sergio
    Rossi, Marta
    Hamzaj, Alketa
    De Angelis, Verena
    De Simone, Valeria
    Caserta, Claudia
    Crino, Lucio
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [9] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sebastian Christoph Schmid
    Alexander Geith
    Alena Böker
    Robert Tauber
    Anna Katharina Seitz
    Markus Kuczyk
    Christoph von Klot
    Jürgen Erich Gschwend
    Axel Stuart Merseburger
    Margitta Retz
    [J]. Advances in Therapy, 2014, 31 : 234 - 241
  • [10] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Schmid, Sebastian Christoph
    Geith, Alexander
    Boeker, Alena
    Tauber, Robert
    Seitz, Anna Katharina
    Kuczyk, Markus
    von Klot, Christoph
    Gschwend, Juergen Erich
    Merseburger, Axel Stuart
    Retz, Margitta
    [J]. ADVANCES IN THERAPY, 2014, 31 (02) : 234 - 241
12345